TY - JOUR AU - Choueiri, T. K. AU - Escudier, B. AU - Powles, T. AU - Tannir, N. M. AU - Mainwaring, P. N. AU - Rini, B. I. PY - 2016 DA - 2016// TI - Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30107-3 DO - 10.1016/S1470-2045(16)30107-3 ID - Choueiri2016 ER - TY - JOUR AU - Choueiri, T. K. AU - Fishman, M. N. AU - Escudier, B. AU - McDermott, D. F. AU - Drake, C. G. AU - Kluger, H. PY - 2016 DA - 2016// TI - Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2839 DO - 10.1158/1078-0432.CCR-15-2839 ID - Choueiri2016 ER - TY - JOUR AU - Choueiri, T. K. AU - Halabi, S. AU - Sanford, B. L. AU - Hahn, O. AU - Michaelson, M. D. AU - Walsh, M. K. PY - 2017 DA - 2017// TI - Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.7398 DO - 10.1200/JCO.2016.70.7398 ID - Choueiri2017 ER - TY - JOUR AU - Escudier, B. AU - Eisen, T. AU - Stadler, W. M. AU - Szczylik, C. AU - Oudard, S. AU - Staehler, M. PY - 2009 DA - 2009// TI - Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.5511 DO - 10.1200/JCO.2008.19.5511 ID - Escudier2009 ER - TY - JOUR AU - Hutson, T. E. AU - Lesovoy, V. AU - Al-Shukri, S. AU - Stus, V. P. AU - Lipatov, O. N. AU - Bair, A. H. PY - 2013 DA - 2013// TI - Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70465-0 DO - 10.1016/S1470-2045(13)70465-0 ID - Hutson2013 ER - TY - JOUR AU - McDermott, D. F. AU - Drake, C. G. AU - Sznol, M. AU - Choueiri, T. K. AU - Powderly, J. D. AU - Smith, D. C. PY - 2015 DA - 2015// TI - Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.1041 DO - 10.1200/JCO.2014.58.1041 ID - McDermott2015 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. AU - George, S. AU - Hammers, H. J. AU - Srinivas, S. PY - 2015 DA - 2015// TI - Nivolumab versus everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Motzer, R. J. AU - Hutson, T. E. AU - Cella, D. AU - Reeves, J. AU - Hawkins, R. AU - Guo, J. PY - 2013 DA - 2013// TI - Pazopanib versus sunitinib in metastatic renal-cell carcinoma JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1303989 DO - 10.1056/NEJMoa1303989 ID - Motzer2013 ER - TY - JOUR AU - Motzer, R. J. AU - Hutson, T. E. AU - Tomczak, P. AU - Michaelson, M. D. AU - Bukowski, R. M. AU - Oudard, S. PY - 2009 DA - 2009// TI - Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.1293 DO - 10.1200/JCO.2008.20.1293 ID - Motzer2009 ER - TY - JOUR AU - Motzer, R. J. AU - Rini, B. I. AU - Bukowski, R. M. AU - Curti, B. D. AU - George, D. J. AU - Hudes, G. R. PY - 2006 DA - 2006// TI - Sunitinib in patients with metastatic renal cell carcinoma JO - JAMA VL - 295 UR - https://doi.org/10.1001/jama.295.21.2516 DO - 10.1001/jama.295.21.2516 ID - Motzer2006 ER - TY - JOUR AU - Sternberg, C. N. AU - Davis, I. D. AU - Mardiak, J. AU - Szczylik, C. AU - Lee, E. AU - Wagstaff, J. PY - 2010 DA - 2010// TI - Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.23.9764 DO - 10.1200/JCO.2009.23.9764 ID - Sternberg2010 ER - TY - JOUR AU - Sternberg, C. N. AU - Hawkins, R. E. AU - Wagstaff, J. AU - Salman, P. AU - Mardiak, J. AU - Barrios, C. H. PY - 2013 DA - 2013// TI - A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.12.010 DO - 10.1016/j.ejca.2012.12.010 ID - Sternberg2013 ER - TY - JOUR AU - Motzer, R. J. AU - Rini, B. I. AU - McDermott, D. F. AU - Redman, B. G. AU - Kuzel, T. M. AU - Harrison, M. R. PY - 2015 DA - 2015// TI - Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.0703 DO - 10.1200/JCO.2014.59.0703 ID - Motzer2015 ER - TY - JOUR AU - Schmid, T. A. AU - Gore, M. E. PY - 2016 DA - 2016// TI - Sunitinib in the treatment of metastatic renal cell carcinoma JO - Ther Adv Urol VL - 8 UR - https://doi.org/10.1177/1756287216663979 DO - 10.1177/1756287216663979 ID - Schmid2016 ER - TY - JOUR AU - Cella, D. AU - Beaumont, J. L. PY - 2016 DA - 2016// TI - Pazopanib in the treatment of advanced renal cell carcinoma JO - Ther Adv Urol VL - 8 UR - https://doi.org/10.1177/1756287215614236 DO - 10.1177/1756287215614236 ID - Cella2016 ER - TY - JOUR AU - Motzer, R. J. AU - Hutson, T. E. AU - McCann, L. AU - Deen, K. AU - Choueiri, T. K. PY - 2014 DA - 2014// TI - Overall survival in renal-cell carcinoma with pazopanib versus sunitinib JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMc1400731 DO - 10.1056/NEJMc1400731 ID - Motzer2014 ER - TY - JOUR AU - Susman, E. PY - 2016 DA - 2016// TI - Pazopanib or sunitinib in metastatic renal cancer: Outcomes are similar JO - Oncology Times VL - 38 UR - https://doi.org/10.1097/01.COT.0000482225.33164.30 DO - 10.1097/01.COT.0000482225.33164.30 ID - Susman2016 ER - TY - STD TI - Morales JMR, Wells JC, Donskov F, Bjarnason GA, Lee JL, Knox JJ, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). J Clin Oncol. 2016;34(suppl 2S):Abstract 544. ID - ref18 ER - TY - JOUR AU - Gore, M. E. AU - Szczylik, C. AU - Porta, C. AU - Bracarda, S. AU - Bjarnason, G. A. AU - Oudard, S. PY - 2015 DA - 2015// TI - Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma JO - Br J Cancer VL - 113 UR - https://doi.org/10.1038/bjc.2015.196 DO - 10.1038/bjc.2015.196 ID - Gore2015 ER - TY - JOUR AU - Dong, Y. AU - Sun, Q. AU - Zhang, X. PY - 2017 DA - 2017// TI - PD-1 and its ligands are important immune checkpoints in cancer JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.13895 DO - 10.18632/oncotarget.13895 ID - Dong2017 ER - TY - STD TI - OPDIVO® (nivolumab) injection [prescribing information]. Bristol-Myers Squibb: Princeton, NJ; 2018. ID - ref21 ER - TY - STD TI - European Medicines Agency. European public assessment report (EPAR) for Opdivo. http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/003985/human_med_001876.jsp&mid=WC0b01ac058001d124. Accessed November 7, 2017. UR - http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/003985/human_med_001876.jsp&mid=WC0b01ac058001d124 ID - ref22 ER - TY - JOUR AU - Hammers, H. J. AU - Plimack, E. R. AU - Infante, J. R. AU - Rini, B. I. AU - McDermott, D. F. AU - Lewis, L. D. PY - 2017 DA - 2017// TI - Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.72.1985 DO - 10.1200/JCO.2016.72.1985 ID - Hammers2017 ER - TY - JOUR AU - Motzer, R. J. AU - Tannir, N. M. AU - McDermott, D. F. AU - Aren Frontera, O. AU - Melichar, B. AU - Choueiri, T. K. PY - 2018 DA - 2018// TI - Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1712126 DO - 10.1056/NEJMoa1712126 ID - Motzer2018 ER - TY - JOUR AU - Ko, J. S. AU - Zea, A. H. AU - Rini, B. I. AU - Ireland, J. L. AU - Elson, P. AU - Cohen, P. PY - 2009 DA - 2009// TI - Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-1332 DO - 10.1158/1078-0432.CCR-08-1332 ID - Ko2009 ER - TY - JOUR AU - Hughes, P. E. AU - Caenepeel, S. AU - Wu, L. C. PY - 2016 DA - 2016// TI - Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer JO - Trends Immunol VL - 37 UR - https://doi.org/10.1016/j.it.2016.04.010 DO - 10.1016/j.it.2016.04.010 ID - Hughes2016 ER - TY - JOUR AU - Atkins, M. B. AU - Plimack, E. R. AU - Puzanov, I. AU - Fishman, M. N. AU - McDermott, D. F. AU - Cho, D. C. PY - 2018 DA - 2018// TI - Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30081-0 DO - 10.1016/S1470-2045(18)30081-0 ID - Atkins2018 ER - TY - STD TI - Lee C, Makker V, Rasco D, Taylor M, Dutcus C, Shumaker R, et al. A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma. Ann Oncol. 2017;28(suppl 5):Abstract 847O. ID - ref28 ER - TY - STD TI - Chowdhury S, McDermott DF, Voss MH, Hawkins RE, Aimone P, Voi M, et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2017;35(suppl):Abstract 4506. ID - ref29 ER - TY - JOUR AU - Ji, Y. AU - Liu, P. AU - Li, Y. AU - Bekele, B. N. PY - 2010 DA - 2010// TI - A modified toxicity probability interval method for dose-finding trials JO - Clin Trials VL - 7 UR - https://doi.org/10.1177/1740774510382799 DO - 10.1177/1740774510382799 ID - Ji2010 ER - TY - STD TI - Amin A, Plimack ER, Infante JR, Ernstoff M, Rini BI, McDermott DF, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib (S) or pazopanib (P) in patients (pts) with metastatic renal cell carcinoma (mRCC). Ann Oncol. 2014;25(suppl 4):Abstract 1052PD. ID - ref31 ER - TY - JOUR AU - Porta, C. AU - Gore, M. E. AU - Rini, B. I. AU - Escudier, B. AU - Hariharan, S. AU - Charles, L. P. PY - 2016 DA - 2016// TI - Long-term safety of sunitinib in metastatic renal cell carcinoma JO - Eur Urol VL - 69 UR - https://doi.org/10.1016/j.eururo.2015.07.006 DO - 10.1016/j.eururo.2015.07.006 ID - Porta2016 ER - TY - JOUR AU - Postow, M. A. AU - Chesney, J. AU - Pavlick, A. C. AU - Robert, C. AU - Grossmann, K. AU - McDermott, D. PY - 2015 DA - 2015// TI - Nivolumab and ipilimumab versus ipilimumab in untreated melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1414428 DO - 10.1056/NEJMoa1414428 ID - Postow2015 ER - TY - JOUR AU - Robert, C. AU - Ribas, A. AU - Hamid, O. AU - Daud, A. AU - Wolchok, J. D. AU - Joshua, A. M. PY - 2018 DA - 2018// TI - Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.75.6270 DO - 10.1200/JCO.2017.75.6270 ID - Robert2018 ER - TY - JOUR AU - Kaufman, H. L. AU - Russell, J. S. AU - Hamid, O. AU - Bhatia, S. AU - Terheyden, P. AU - D'Angelo, S. P. PY - 2018 DA - 2018// TI - Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-017-0310-x DO - 10.1186/s40425-017-0310-x ID - Kaufman2018 ER - TY - JOUR AU - Petrylak, D. P. AU - Powles, T. AU - Bellmunt, J. AU - Braiteh, F. AU - Loriot, Y. AU - Morales-Barrera, R. PY - 2018 DA - 2018// TI - Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2017.5440 DO - 10.1001/jamaoncol.2017.5440 ID - Petrylak2018 ER - TY - JOUR AU - Choueiri, T. K. AU - Larkin, J. AU - Oya, M. AU - Thistlethwaite, F. AU - Martignoni, M. AU - Nathan, P. PY - 2018 DA - 2018// TI - Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30107-4 DO - 10.1016/S1470-2045(18)30107-4 ID - Choueiri2018 ER - TY - STD TI - Atkins MB, McDermott DF, Powles P, Motzer RJ, Rini BI, Fong L, et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol. 2017;35(15 suppl):Abstract 4505. ID - ref38 ER - TY - STD TI - Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2018;36(6 suppl):Abstract 578. ID - ref39 ER - TY - STD TI - Rini BI, Powles T, Chen M, Puhlmann M, Atkins MB. Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2017;35(suppl):Abstract TPS4597. ID - ref40 ER - TY - STD TI - Choueiri TK, Rini BI, Larkin JMG, Bjarnason GA, Gravis G, Gurney H, et al. Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101). J Clin Oncol. 2017;35(suppl):Abstract TPS4594. ID - ref41 ER - TY - STD TI - Motzer RJ, Grunwald V, Hutson TE, Porta C, Powles T, Eto M, et al. A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2017;35(suppl):Abstract TPS4595. ID - ref42 ER - TY - STD TI - Choueiri TK, Apolo AB, Powles T, Escudier B, Aren OR, Shah A, et al. A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER). J Clin Oncol. 2018;36(suppl):Abstract TPS4598. ID - ref43 ER -